Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 8/20 | 0.49 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323052 | 0.94 | MERTK (0.44) | MERTKAXLTYRO3LMNAFLT3 | |
| SCHEMBL10324360 | 0.93 | MERTK (0.41) | MERTKAXLTYRO3FLT3CCNT1 | |
| SCHEMBL10323111 | 0.92 | FLT3 (0.47) | MERTKAXLTYRO3LMNAFLT3 | |
| SCHEMBL10322157 | 0.91 | MERTK (0.43) | MERTKAXLTYRO3LMNAFLT3 | |
| SCHEMBL10322901 | 0.90 | FLT3 (0.46) | MERTKAXLTYRO3LMNAFLT3 | |
| SCHEMBL10321987 | 0.86 | MERTK (0.49) | MERTKAXLTYRO3TNK2MAPK8 | |
| SCHEMBL10322268 | 0.86 | MERTK (0.54) | MERTKAXLTYRO3LMNATNK2 | |
| SCHEMBL10323692 | 0.85 | MERTK (0.65) | MERTKAXLTYRO3TNK2 | |
| SCHEMBL10322254 | 0.82 | MERTK (0.42) | MERTKAXLTYRO3TNK2JAK3 | |
| SCHEMBL14664472 | 0.80 | MERTK (0.48) | MERTKAXLTYRO3LMNATNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362023-B2 | Pyrazolo pyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012098068-A1 | PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | BIODURO (BEIJING) COMPANY LTD. (CN) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184508-A1 | PYRAZOLO PYRIMIDINES | TYMS, TYMP, TP53 | MERTK 2006/4885AXL 1246/4885TYRO3 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.